JP2023123726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023123726A5 JP2023123726A5 JP2023105929A JP2023105929A JP2023123726A5 JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5 JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hvr
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017091955 | 2017-05-02 | ||
| JP2017091955 | 2017-05-02 | ||
| PCT/JP2018/017495 WO2018203567A1 (en) | 2017-05-02 | 2018-05-02 | Cytotoxicity-inducing therapeutic agent |
| JP2019559378A JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Division JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023123726A JP2023123726A (ja) | 2023-09-05 |
| JP2023123726A5 true JP2023123726A5 (cg-RX-API-DMAC7.html) | 2025-08-05 |
Family
ID=64016153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Pending JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
| JP2023105929A Pending JP2023123726A (ja) | 2017-05-02 | 2023-06-28 | 細胞傷害誘導治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Pending JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20200123256A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3619238A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020518584A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018203567A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201815863T4 (tr) | 2010-11-30 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | Sitotoksisiteyi indükleyen terapötik madde. |
| CN109111524B (zh) | 2011-10-31 | 2022-10-28 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| KR102568808B1 (ko) | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
| AU2015260230A1 (en) | 2014-05-13 | 2016-11-17 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| AU2018211985B2 (en) | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| CN112654363A (zh) | 2018-07-09 | 2021-04-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| US12454580B2 (en) | 2020-04-10 | 2025-10-28 | Regeneron Pharmaceuticals, Inc. | FRB antibodies |
| CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
| KR20230109668A (ko) | 2020-11-16 | 2023-07-20 | 서로젠 오퍼레이팅, 인크. | 간-특이적 Wnt 신호 증강 분자 및 그의 용도 |
| EP4288458A1 (en) * | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| JP2025508949A (ja) * | 2022-02-28 | 2025-04-10 | アデプト セラピューティクス インコーポレイテッド | 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106029696B (zh) * | 2013-12-17 | 2020-07-28 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| CA2946308A1 (en) * | 2014-04-21 | 2015-10-29 | Abbvie Stemcentrx Llc | Novel anti-rnf43 antibodies and methods of use |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| HK1250997A1 (zh) * | 2015-05-01 | 2019-01-18 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
-
2018
- 2018-05-02 EP EP18794608.2A patent/EP3619238A4/en active Pending
- 2018-05-02 WO PCT/JP2018/017495 patent/WO2018203567A1/en not_active Ceased
- 2018-05-02 JP JP2019559378A patent/JP2020518584A/ja active Pending
- 2018-05-02 US US16/605,556 patent/US20200123256A1/en not_active Abandoned
-
2023
- 2023-06-28 JP JP2023105929A patent/JP2023123726A/ja active Pending
- 2023-12-11 US US18/535,310 patent/US20240239890A1/en active Pending